Introduction
Globally the numbers of overweight, obese and severely obese people are increasing rapidly. High incidences of obesity and overweight have been documented for the South African population (Table Ia and This surgical intervention can achieve long-term sustained weight loss and often induces resolution of comorbidities such as diabetes, sleep apnoea, hyperlipidaemia and hypertension (Table II) . 1 Venous thromboembolism (VTE) may occur after bariatric surgery which can cause significant morbidity and mortality. 46% of the world's 400 million obese people are from the developing world. 4 
Surgical risk
The positive pressure during laparoscopic inflation has been associated with oxidative stress during surgery which, in turn, will cause endothelial dysfunction and platelet aggregation. The position of the patient, tilted feet down to 15°, as well as the duration of the operation, both contribute to decreased blood flow. The duration is influenced by the type of surgery performed, e.g. laparoscopic gastric banding usually being the quickest and thus with the lowest risk of VTEs. 
Patient risk factors
Adipose tissue is one of the main sources of inflammatory mediators, including interleukin-6. This cytokine stimulates platelet-aggregating factor-1(PAF-1). Plasminogen activator inhibitor-1 levels are increased in obesity partly due to increased gene expression in the adipocytes. In addition, levels of circulating antithrombin levels are low. A sedentary lifestyle and right cardiac insufficiency also contribute to decreased venous flow. Overall, obesity is a prothrombotic condition.
There are several other factors that have to be considered when attempting to stratify risk for VTE during bariatric surgery:
Frezza et al 5 indicate that patients are considered high risk if they have:
• Heart failure, a BMI ≥ 50 kg/m 
Non-pharmacological prophylaxis
There is no consensus on the best prophylactic regimen for VTEs 
Inferior vena cava filters

Recommendations
Screening
There have been some reports that showed an increase in thrombophilias in the obese patients compared to the non-obese. 12 However, it is not considered cost effective to do a full thrombotic profile in every patient.
It is important to note on the history if there has been a prior deep vein thrombosis or pulmonary embolism. If there were no obvious precipitating causes for this event, then a thrombophilia screen can be considered. This screen cannot be performed on patients who are on long-term warfarin therapy. Preoperative factor Xa levels should be measured as a baseline marker.
Prophylaxis
Subcutaneous LMWH is the easiest to administer. The dose is usually: • It is advised that a baseline anti-Xa level should be measured.
• LMWH can be started the day before surgery and continued intraand postoperatively.
• Enoxaparin 40 mg daily is most commonly used and can be titrated against anti-Xa levels if indicated .
• Most patients need to continue with anticoagulation for 7-21 days depending of individual risk assessment.
• In patients with a very high risk profile for VTEs, LMWH should be continued for a minimum of three weeks and possibly for up to six weeks.
• Before theatre, elastic stockings and compression devices must be fitted until the patient is fully mobilised.
• Mobilisation should start within 12 hours if no operative complications occur.
• In patients weighing more than 250 kg, an inferior vena cava filter can be fitted.
Available evidence to date suggests that adherence to guidelines and recommendations will improve, but not necessarily eliminate the incidence of VTE.
